Skip to main content
Entrada Therapeutics, Inc. logo

Entrada Therapeutics, Inc. — Investor Relations & Filings

Ticker · TRDA ISIN · US29384C1080 US Manufacturing
Open in API
Filings indexed 422 across all filing types
Latest filing 2023-02-09 Regulatory Filings
Country US United States of America
Listing US TRDA

About Entrada Therapeutics, Inc.

https://www.entradatx.com/

Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing a new class of medicines to treat devastating diseases. The company's proprietary Endosomal Escape Vehicle (EEV) platform is designed to enable the intracellular delivery of a wide range of therapeutics, allowing access to targets that have historically been considered undruggable. Entrada's development pipeline is concentrated on rare conditions, with programs targeting neuromuscular diseases, including Duchenne muscular dystrophy, as well as ocular diseases. The company's mission is to transform the lives of patients by establishing EEV-based therapeutics as a new treatment modality.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Entrada Therapeutics, Inc. It announces the closing of a Strategic Collaboration and License Agreement and a Sublicense Agreement with Vertex Pharmaceuticals, as well as the sale of shares to Vertex. The document includes references to previous filings and agreements but does not contain detailed financial statements or comprehensive financial analysis. It primarily serves as a regulatory announcement of recent corporate events and transactions. The document length is about 5,178 characters, which is relatively short and consistent with a regulatory announcement rather than a full report. Therefore, this filing fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings like Form 8-K that do not fit other specific categories.
2023-02-09 English
SEC SCHEDULE 13G
Major Shareholding Notification
2023-02-06 English
FORM 4
Director's Dealing
2023-01-30 English
FORM 4
Director's Dealing
2023-01-10 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content describes an announcement of a clinical candidate selection and includes a press release as an exhibit. There are no financial statements or detailed financial data presented. The document length is 3117 characters, which is relatively short and primarily serves as an announcement rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2023-01-09 English
FORM 4
Director's Dealing
2023-01-03 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.